Yüklüyor......
Biological evaluation of a novel sorafenib analogue, t-CUPM
Sorafenib (Nexavar(®)) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. The use of structural analogues and derivatives of sorafenib has enabled the elucidation of critical targets and mechanism(s) of cell death for human cancer lines. We prev...
Kaydedildi:
| Yayımlandı: | Cancer Chemother Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4400119/ https://ncbi.nlm.nih.gov/pubmed/25413440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2626-2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|